REG - EKF Diagnostics Hldg - Three-year Hematology purchasing agreement

EKF Diagnostics HoldingsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260303:nRSC9893Ua&default-theme=true

RNS Number : 9893U  EKF Diagnostics Holdings PLC  03 March 2026

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Three-year Hematology purchasing agreement

with Blood Centers of America

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics
business, announces that it has signed a three year Group purchasing agreement
with Blood Centers of America Inc ("BCA"), the largest blood supply network in
the U.S. and uniquely positioned to sustain, advocate and mobilize for the
nation's blood supply. BCA's membership consist of more than 60 independent
community blood centers, which collect and distribute 50% of the nation's
blood supply. For more information: https://bca.coop/ (https://bca.coop/)

 

This new agreement provides pricing for the DiaSpect Tm
(https://www.ekfdiagnostics.com/point-of-care/hematology/diaspect/) Hand-held
hemaglobin analyzer and associated consumable cuvettes. Pricing is also
provided for an EKF Link IT License, which enables a paperless workflow and
streamlined quality control management, allowing operators to focus on the
patients and donors they serve instead of the analyzer in use. EKF Link
enables new functions like Hematocrit calculation, quality control management,
and patient data management. EKF will also provide dedicated product training,
including support with product evaluations as well as validation and
verification activities to fully integrate the DiaSpect Tm offering.

 

Commenting, Sam Keith, SVP of Supply Chain, said: "BCA are pleased to be
partnering with EKF on a master supply agreement following on from the high
interest EKF generated at the Association for the Advancement of Blood &
Biotherapies Annual Meeting in San Diego in October 2025. The Company
presented a poster demonstrating the exceptional efficacy of the DiaSpect Tm
product, especially when combined with the EKF Link connectivity solution."

 

The poster is available to view here:
http://ekfdiagnostics.com/events/aabb-2025/poster
(http://ekfdiagnostics.com/events/aabb-2025/poster)

 

Commenting, Gavin Jones, Chief Executive Officer, said: "We are very pleased
with the early successes we are seeing as we implement our five-year strategic
development plan. In that, we identified Hemoglobin testing as the most
significant growth opportunity within our Point-of-Care (POC) portfolio and we
remain steadfast in our ambition to become number 1 in global POC Hematology
testing. The agreement with BCA is a significant milestone in this ambition,
with the US blood bank market considered to be one of the largest addressable
markets in the world."

 

The person responsible for arranging the release of this Announcement

on behalf of the Company is Gavin Jones, Chief Executive Officer.

 

 EKF Diagnostics Holdings plc                                www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Julian Baines, Executive Chair                               via Walbrook PR
 Gavin Jones, Chief Executive Officer

 Singer Capital Markets (Nominated Adviser & Broker)                                       Tel: +44 (0)20 7496 3000
 Phil Davies / Patrick Weaver

 Walbrook PR Limited              Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Alice Woodings    Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

 

EKF is an AIM-listed global diagnostics business focussed on:

 

 ●    Point-of-Care analysers in the key areas of Hematology and Diabetes
 ●    Life Sciences services provide specialist manufacture of enzymes and custom
      products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing
sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRAKBBNPBKDPNK



            Copyright 2019 Regulatory News Service, all rights reserved